retatrutide safety clinical trial results Retatrutide vs Ozempic: Trial Comparisons Investigating the “efficacy and safety

The former is currently awaiting FDA approval for a handful of oral, daily GLP-1 agonists, while the latter is developing combination therapies that use their muscle-preserving antibodies, trevogrumab and garetosmab, alongside GLP-1 drugs like Wegovy and Ozempic, to improve fat loss while preserving muscle mass

Plaintiffs allege the companies misled consumers about the risks associated with the drugs, including potential side effects and safety concerns

GLP-1 receptor agonists are mainly administered through the parenteral route due to poor oral bioavailability and degradation in the GI tract

Protecting Peptide Integrity Minimize exposure to light by storing the vial in the original box or a dedicated dark container